Competition & Markets Authority
Tribunal upholds CMA decision on pharma collusion and £1.2m fine
The Competition Appeal Tribunal has today upheld the CMA’s finding that Lexon broke competition law, dismissing Lexon’s appeal.
Last year, the Competition and Markets Authority (CMA) concluded its investigation into the supply of nortriptyline, a drug relied on by thousands of patients daily to relieve symptoms of depression.
The CMA found that pharmaceutical firm Lexon, along with King Pharmaceuticals Ltd and Alissa Healthcare Research Ltd, had illegally shared commercially sensitive information to try to keep nortriptyline prices up. From 2015 to 2017, when the cost of the drug was falling, the 3 suppliers exchanged information about prices, the volumes they were supplying, and Alissa’s plans to enter the market.
As a result, the CMA fined all 3 companies, fining Lexon a total of £1,220,383. Lexon maintained that it had not broken the law and so appealed against the decision and the fine.
Today’s judgment from the Competition Appeal Tribunal (CAT) unanimously dismissed all of Lexon’s grounds of appeal, upholding both the CMA’s finding that the firm broke competition law, and the fine.
The judgment now clears the way for the CMA to continue its director disqualification application against Mr Pritesh Sonpal, a Lexon director, who was directly involved in the information exchange. The application was on hold in the High Court, pending the CAT’s decision.
Andrea Coscelli, Chief Executive of the CMA, said:
We welcome the decision from the Competition Appeal Tribunal to dismiss Lexon’s appeal in its entirety and support the findings of our investigation, including our decision to fine the firm over £1.2 million.
Lexon illegally exchanged competitively-sensitive information to try and keep prices up, meaning the NHS – and ultimately the UK taxpayer – could have been paying over the odds for this important drug.
Such behaviour is unacceptable. We will continue to crack down on companies that seek to break the law and will be keeping a close eye on this sector.
For more information, visit the Nortriptyline investigation: anti-competitive agreement and conduct case page.
Latest News from
Competition & Markets Authority
Bellis’ purchase of Asda raises some competition concerns21/04/2021 12:20:00
The CMA has found that Bellis’ completed £6.8bn purchase of Asda could lead to higher petrol prices in some parts of the country.
UK, Australia and Germany issue statement on merger control20/04/2021 15:10:00
Three leading competition authorities come together to stress importance of merger enforcement for healthy economic recovery.
CAT increases fine after musical instrument firm breaks settlement bargain20/04/2021 10:15:00
The CMA has welcomed a Competition Appeal Tribunal judgment dismissing an appeal against a fine it imposed, instead increasing the fine from £4m to £5m.
Competition concerns remain about FNZ’s purchase of GBST15/04/2021 15:10:00
The CMA has provisionally found that a deal between FNZ and GBST would raise significant competition concerns, following its re-examination of available evidence.
CMA provisionally clears merger of Virgin and O214/04/2021 10:15:00
The CMA has provisionally cleared the proposed merger of Virgin Media and Virgin Mobile with O2.
CMA intervention leads to further Facebook action on fake reviews09/04/2021 11:20:00
CMA action results in Facebook going further to combat the trading in fake and misleading reviews on Facebook.com and Instagram.com.
New watchdog to boost online competition launches07/04/2021 12:22:00
A tough new regulator to help make sure tech giants such as Facebook and Google cannot exploit their market dominance to crowd out competition and stifle innovation online has launched.
CMA clears Uber and Autocab deal30/03/2021 12:20:00
The CMA yesterday announced that it has cleared Uber’s purchase of Autocab, following a Phase 1 merger investigation.